source
- STAT+: Triple hormone receptors, a monthly obesity drug, and a bittersweet endingYou're reading the web edition of STAT's ADA in 30 Seconds, from the American Diabetes Association's annual conference in New Orleans.STAT · 1mo ago↗ source
- STAT+: Lilly shares safety, tolerability data on its next-gen obesity drugEli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.STAT · 1mo ago↗ source
- #ADA26: Pfizer's monthly shot shows effect on obesity, diabetesThe long-acting GLP-1 shot that was the centerpiece of Pfizer’s acquisition of Metsera last year looks effective in patients with both obesity and diabetes, according to data presented Saturday. Be…Endpoints · 1mo ago